As ligands that activate the Wnt/β-catenin signaling pathway, WNTs are widely implicated in the development of glioma, and clinical data show that expression levels of WNT5A, WNT3A and WNT1 are closely correlated with the overall survival of patients with glioma [27–29]. Here, WNT3A is linked to central nervous system cancer.